Novel agomelatine crystal form L and preparation method thereof

A technology of agomelatine crystal and L type, which is applied in the field of medicinal chemical synthesis, can solve the problems of process stability, poor repeatability, harsh preparation conditions, and is difficult to large-scale industrial production, and achieves remarkable medicinal effect and operation. Simple, high bioavailability

Inactive Publication Date: 2012-12-26
FUJIAN COSUNTER PHARMA CO LTD
View PDF16 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Although the above-mentioned patents describe the preparation methods of agomelatine in different crystal forms, the methods introduced in the above-mentioned documents have the disadvantages of poor process stability and repeatability, and the preparation conditions are relatively harsh, making it difficult to be suitable for large-scale industrial production

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel agomelatine crystal form L and preparation method thereof
  • Novel agomelatine crystal form L and preparation method thereof
  • Novel agomelatine crystal form L and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Take 1g of agomelatine (purity 99.5%) in a 100ml reaction bottle, add 10ml of toluene and stir at room temperature, it does not dissolve, heat to 80°C, still not completely dissolved, then add another 10ml of toluene, the solid dissolves completely. Stop heating, open to cool naturally, precipitate crystals, until the toluene is completely volatilized, transfer to 40°C for vacuum drying. Obtained 0.98g solid with a yield of 98%, a purity of 99.58%, and a residual solvent of toluene of 0.015% (according to the requirements of the 2010 edition of the Chinese Pharmacopoeia, the residual toluene solvent of the raw material should be ≤0.089%), melting point: 107.3-108.8°C, and X-ray powder diffraction pattern see attached figure 1 .

Embodiment 2

[0036] Take 1g of agomelatine (purity 99.5%) in a 100ml reaction bottle, add 20ml of isopropyl ether and stir at room temperature, it does not dissolve, heat to 80°C, still not completely dissolved, then add 20ml of isopropyl ether, the solid is completely dissolve. Stop heating, open to cool naturally, precipitate crystals, until the isopropyl ether volatilizes completely, transfer to 40°C for vacuum drying. Obtained 0.99g solid, the yield was 99%, the purity was 99.55%, and the residual solvent of isopropyl ether was 0.12% (according to the requirements of the Chinese Pharmacopoeia 2010 edition, the residual solvent of isopropyl ether in raw materials should be ≤0.5%), melting point: 107.5- 108.7°C, its X-ray powder diffraction pattern is shown in the attached figure 2 .

Embodiment 3

[0038]Take 5g of agomelatine (purity 99.5%) in a 250ml reaction bottle, add 100ml of toluene and stir at room temperature, if it does not dissolve, heat it to 80°C, and the solid will dissolve completely. Stop heating, open to cool naturally, precipitate crystals, until the toluene is completely volatilized, transfer to 40°C for vacuum drying. Obtained 4.96g of solid, the yield was 99.2%, the purity was 99.51%, the residual solvent of toluene was 0.018% (according to the requirements of the Chinese Pharmacopoeia 2010 edition, the residual toluene solvent of the raw material drug should be ≤0.089%), the melting point: 107.2-108.6 ° C, its X-ray powder diffraction pattern see attached figure 1 .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
Login to view more

Abstract

The invention belongs to the technical field of pharmaceutical chemical synthesis and relates to a novel agomelatine crystal form L and a preparation method thereof. The preparation method of the novel Agomelatine crystal form L comprises the following steps of: adding an agomelatine crude product into a solvent and heating and dissolving the agomelatine crude product; then cooling to the room temperature, naturally volatilizing to be dry; and finally obtaining the product through vacuum drying.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical chemical synthesis, and relates to a new crystal form L of agomelatine and a preparation method thereof. Background technique [0002] The chemical name of agomelatine is N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, and its structural formula is shown in the following formula (I). Its trade name is Valdoxan, which is the first melatonin antidepressant developed by Servier in France, and it was launched in Germany and the UK in 2009. It can effectively treat depression, improve sleep parameters and maintain sleep quality. features of sexual function. [0003] [0004] Agomelatine is not only the first melatonin receptor agonist, but also a 5-hydroxytryptamine 2C (S-HTx) receptor antagonist. A large number of animal experiments and clinical studies have shown that the drug has the effects of antidepressant, anti-anxiety, regulating sleep rhythm and regulating the biological clock. At the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07C233/18C07C231/24A61K31/165A61P25/24A61P25/22A61P25/20
Inventor 姚建堤陈首鹤陈仕魁杨喜鸿苏葳
Owner FUJIAN COSUNTER PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap